Find insight on Merck KGaA, Oceania Healthcare and more in the latest Market Talks covering the health care sector.

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Plants are very important living things. They have lots of jobs, such as providing animals with food and releasing oxygen into the air. To survive and carry out these jobs, they all need three ...

which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties to its name-brand counterpart.

This paper investigates the importance of Trustworthy Machine Learning (ML) in the context of Multiple Sclerosis (MS) research and care. Due to the complex and individual nature of MS, the need for ...